- SCIEX to present new applications for CESI-MS technology at global symposium
- LGC announces plans to invest in new GMP analytical capability
SCIEX to present new applications for CESI-MS technology at global symposium
SCIEX (MA, USA) recently announced novel applications for capillary electrophoresis–mass spectrometry (CESI-MS), a unique technology for separating minute complex samples. This announcement coincides with the 3rd Global CESI-MS Symposium (Leiden University Medical Center, the Netherlands; 10–11 October 2018) where experts from the field are due to discuss the impact and uses of CESI-MS in the field of analytics.
CESI-MS is designed to separate complex small samples without facing complications related to dead volumes or carryover. The technology is reported to offer ultra low-flow separation along with high-performance, high-resolution, accurate MS, adding to SCIEX’s existing wide range of ESI-MS front-end solutions. As a result, this methodology has the potential to advance analytics in the fields of pharmaceuticals, proteomics and metabolomics, as well as food and environmental monitoring.
The impact of the CESI-MS technology are due to be discussed at the global symposium, including: Richard Snell (GSK, UK) discussing ‘Using CESI-MS to quantify mAbs with a pseudo intact or intact approach;’ Claire Eyers from Liverpool University (UK) presenting, ‘The top to bottom of protein phosphorylation using CESI-MS;’ as well as Sven Stuke (Bayer, Germany) speaking on: ‘The detection of pesticide metabolite TFA by CESI-MS.’
Andreas Krupke, CESI-MS Product Manager at SCIEX, concluded: “The Symposium brings together internationally renowned researchers and innovators as they present their latest advances in CESI-MS. This interactive event enables participants to gain valuable know-how from experts across a variety of fields that will bring a competitive edge to any lab working within compound identification and quantification.”
Source: SCIEX Presenting New Applications at Global CESI-MS Symposium 2018 press release
LGC announces plans to invest in new GMP analytical capability
LGC Axolabs (Kulmbach, Germany) have announced plans to expand the capacity of its specialist therapeutic oligonucleotide development solutions business, and create a new GMP analytical capability, following a recent significant investment.
The company intends to focus the expansion on their Kulmbach site, incorporating new 800m² labs comprising additional bioanalysis and synthetic chemistry labs, as well as a new GMP CMC analytical capability for batch release testing of oligonucleotide-based drug substances and products. The labs are due to open in February 2019.
Hans-Peter Vornlocher, Managing Director at LGC Axolabs, explained: “This investment provides a platform for growth of our oligonucleotide therapeutics development activities, expanding our total site capacity to around 4,500m2 and to around 100 scientists. We are also glad to be able to add GMP analytical services as a new dimension to our biology, synthetic chemistry and other analytical services.”
This news follows on from LGC’s announcements last year of expansion of their Petaluma site, as well as the recent completion of the first phase of long term improvements to their labs in Fordham, UK.
David Griffiths, Managing Director of Pharma and Health Solutions, LGC, concluded: “We’re excited about this expansion which not only supports growth of our Kulmbach site but is also part of a larger international growth strategy for LGC’s drug development solutions business giving access and greater flexibility for our clients.”
Source: LGC invests in new GMP analytical capability press release